US2001014685A1PendingUtilityA1

Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction

44
Assignee: USA DOCTORS PRODUCTS INCPriority: Jan 14, 1998Filed: Mar 2, 2001Published: Aug 16, 2001
Est. expiryJan 14, 2018(expired)· nominal 20-yr term from priority
Inventors:An-Hao Lin
A61K 31/425A61K 47/10A61K 9/0019A61K 31/47A61K 31/19A61K 31/20A61K 45/06
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An injectable pharmaceutical composition for treatment of erectile dysfunction. The composition includes prostaglandin E-1, and optionally further includes levsin and/or additional vasodilators such as diltiazem HCl, verapamil, chlorpromazine, d,L-hyoscyamine, and 6,7-dimethoxy-1-veratrylisoquinoline HCl. The composition is effective for long-term restoration of normal erectile function to a patient having erectile dysfunction. The ability to reverse erectile dysfunction may be further enhanced by the inclusion of vitamin B-6, B-12, folic acid, and/or TPA. Also disclosed are methods for treatment and reversal of erectile dysfunction by injecting the pharmaceutical composition into the penis, either by subcutaneous or intracavernosal injection.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for treatment of a patient having erectile dysfunction, comprising the steps of: 
 providing a pharmaceutical composition comprising 0.0001-60 μg prostaglandin E-1 and d,L-hyoscyamine; and    injecting the patient with the pharmaceutical composition.    
     
     
         2 . The method of    claim 1   , wherein the pharmaceutical composition further comprises a calcium channel blocker.  
     
     
         3 . The method of    claim 1   , wherein the step of injecting the patient with the pharmaceutical composition includes the use of a needle.  
     
     
         4 . The method of    claim 1   , wherein the treatment restores normal erectile function to the patient.  
     
     
         5 . The method of    claim 1   , wherein the injection is subcutaneous.  
     
     
         6 . The method of    claim 1   , wherein the injection is intracavernosal.  
     
     
         7 . The method of    claim 1   , wherein the pharmaceutical composition further comprises 0-10 mg vitamin B-12.  
     
     
         8 . The method of    claim 1   , wherein the pharmaceutical composition further comprises 0-10 mg vitamin B-6.  
     
     
         9 . The method of    claim 1   , wherein the pharmaceutical composition further comprises 0-1 mg folic acid.

Join the waitlist — get patent alerts

Track US2001014685A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.